Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hind Rafei

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based RegimenMark Parta, Nirali N Shah, Kristin Baird, et al.
Iscience|July 3, 2024
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profilesShan He, Matthew M Gubin, Hind Rafei, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profilesShan He, Matthew M Gubin, Hind Rafei, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2017
Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective AnalysisArafat Tfayli, Hind Rafei, Alain Mina, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Frontiers in Immunology|October 7, 2022
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopeniaBijender Kumar, Vahid Afshar-Kharghan, Mayela Mendt, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2024
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation TherapyGohar S Manzar, Stephanie O Dudzinski, Alison K Yoder, et al.
Cell Reports|January 4, 2025
Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cellsLuciana Melo Garcia, Achintyan Gangadharan, Pinaki Banerjee, et al.
Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based RegimenMark Parta, Nirali N Shah, Kristin Baird, et al.
Iscience|July 3, 2024
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profilesShan He, Matthew M Gubin, Hind Rafei, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profilesShan He, Matthew M Gubin, Hind Rafei, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2017
Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective AnalysisArafat Tfayli, Hind Rafei, Alain Mina, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Frontiers in Immunology|October 7, 2022
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopeniaBijender Kumar, Vahid Afshar-Kharghan, Mayela Mendt, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2024
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation TherapyGohar S Manzar, Stephanie O Dudzinski, Alison K Yoder, et al.
Cell Reports|January 4, 2025
Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cellsLuciana Melo Garcia, Achintyan Gangadharan, Pinaki Banerjee, et al.
Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Pageof 6